| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H17ClN4O |
| Molecular Weight | 304.775 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC(COC2=NC(=CN=C2)N3CCNCC3)=CC=C1
InChI
InChIKey=PCWGGOVOEWHPMG-UHFFFAOYSA-N
InChI=1S/C15H17ClN4O/c16-13-3-1-2-12(8-13)11-21-15-10-18-9-14(19-15)20-6-4-17-5-7-20/h1-3,8-10,17H,4-7,11H2
| Molecular Formula | C15H17ClN4O |
| Molecular Weight | 304.775 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
CP-809101 is a potent, functionally selective 5-HT(2C) agonist that displays approximately 100% efficacy in vitro. CP-809101 has a pharmacological profile similar to that of the atypical antipsychotics with low extrapyramidal symptom liability. CP-809101 was active in novel object recognition, an animal model of cognitive function. It had promising results in animal models of obesity and psychosis.
CNS Activity
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Rats: rats were used to test the effect of varying doses of
CP-809101 (1–3 mg/kg SC) on nicotine self-administration
according to a repeated-measures design, with each animal receiving each dose and vehicle in a counterbalanced sequence, with 2–4 days between cycles.
Route of Administration:
Other
